Actively Recruiting
Antisecretory Factor Glioblastoma Phase 2
Led by Peter Siesjö · Updated on 2026-01-09
300
Participants Needed
1
Research Sites
202 weeks
Total Duration
On this page
Sponsors
P
Peter Siesjö
Lead Sponsor
L
Lund University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
CONDITIONS
Official Title
Antisecretory Factor Glioblastoma Phase 2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathology verified glioblastoma or astrocytoma grade 4
- Age 18-75 years
- Surgical treatment by resection
- Scheduled concomitant radiochemotherapy or chemotherapy
- Provided informed consent
You will not qualify if you...
- No informed consent
- Allergy to egg yolk
- Only surgical biopsy without resection
- Receiving only radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Skåne University Hospital
Lund, Sweden, 22185
Actively Recruiting
Research Team
P
Peter Siesjö, MD, PhD
CONTACT
J
Johan Bengzon, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here